Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2004

View Archived Issues

Crucell presents human anti-OX40 receptor agonistic antibodies for cancer therapy

Novel PEPCK inhibitors and their use in type 2 diabetes reported by Roche

Novuspharma team identifies new VEGF production inhibitors

Novel PARP inhibitors prepared and tested at Pfizer

Merck and Isis present new NS5B inhibitors for use in HCV infection

New analgesic bradykinin B1 antagonists in early development at Fournier

Novel antiangiogenic agents covered by Pfizer patent

New vitamin D-based CYP24 inhibitors and their use claimed by Johns Hopkins U. and Cytochroma

Enrollment ceased in phase IIb/III trial of Ad5FGF-4

Expert advisory board to guide BioMarin's PKU programs

A-221-HIV to enter clinical trials in Latin America

CAT continues progress in 2004

Inspire to conduct additional trial for diquafosol following FDA meeting

Takeda exercises rights to ATL-962 for Japan

Novartis files global applications for new Diovan indication

CE Mark for Celacade for chronic heart failure

Genencor hepatitis B vaccine to enter phase I this month

sNDA for intravenous administration of Remodulin

Bentley completes phase I study of proprietary intranasal insulin formulation

Botulinum toxin B reported to improve drooling in Parkinson's disease

Further evidence for the therapeutic benefits of thalidomide in cutaneous sarcoidosis

Survival benefit found with tesmilifene plus doxorubicin in recurrent/metastatic breast cancer

Alendronate found effective in the prevention of bone disease in patients with cystic fibrosis

Promising effects induced by ziprasidone in Huntington's disease

FDA approval for Spiriva HandiHaler

NDA submission for YM-087 for hyponatremia

European submission for YM-617 TOCAS

Approvable letter for Emsam

ECO-04601 inhibits tumor growth in animal model of glioma

Pfizer files IND for antibody product candidate

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.